SCHEMBL30456331

SCHEMBL30456331

CP(C)(=O)c1c(C(=O)O)ccc2cc[nH]c12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.51
PTPRC P08575 2/20 0.40
PTPN2 P17706 2/20 0.40
PTPN1 P18031 2/20 0.40
PTPRB P23467 2/20 0.40
PTPRE P23469 2/20 0.40
PTPN6 P29350 2/20 0.40
PDPK1 O15530 1/20 0.39
ALDH1A1 P00352 2/20 0.37
KDM4E B2RXH2 2/20 0.37
BRD4 O60885 1/20 0.37
TAF1 P21675 1/20 0.37
BRPF1 P55201 1/20 0.37
CREBBP Q92793 1/20 0.37
CECR2 Q9BXF3 1/20 0.37
BRD9 Q9H8M2 1/20 0.37
HPGD P15428 1/20 0.37
ENPP2 Q13822 1/20 0.37
HSD17B10 Q99714 1/20 0.37
XDH P47989 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25364866 0.83 PIM3 (0.41) KEAP1PTPRCPTPN2PTPN1PTPRB
SCHEMBL31122414 0.83 PIM3 (0.41) KEAP1PTPRCPTPN2PTPN1PTPRB
SCHEMBL12377148 0.76 KEAP1 (0.58) KEAP1PTPRCPTPN2PTPN1PTPRB
SCHEMBL22076261 0.73 KEAP1 (0.58) KEAP1PTPRCPTPN2PTPN1PTPRB
SCHEMBL23538104 0.73 KEAP1 (0.58) KEAP1PTPRCPTPN2PTPN1PTPRB
SCHEMBL2285281 0.73 KEAP1 (0.58) KEAP1PTPRCPTPN2PTPN1PTPRB
SCHEMBL28878115 0.72 KEAP1 (0.53) KEAP1PTPRCPTPN2PTPN1PTPRB
SCHEMBL29492540 0.71 BRD4 (0.40) KEAP1BRD4TAF1BRPF1CREBBP
SCHEMBL30456277 0.71 KEAP1 (0.51) KEAP1PTPRCPTPN2PTPN1PTPRB
SCHEMBL336234 0.68 KEAP1 (1.00) KEAP1PDPK1ALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250145632-A1 Pyrimidine Heterocyclic Compound, Preparation Method Thereof and use Thereof in Medicine INSILICO MEDICINE IP LIMITED (HK) 2025-05-08 US disclosed
EP-4455132-A1 PYRIMIDINE HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE Insilico Medicine IP Limited (HK) 2024-10-30 EP disclosed
CN-118647607-A Pyrimidine heterocyclic compounds, process for preparing the same and pharmaceutical use thereof 英矽智能科技(上海)有限公司 2024-09-13 CN disclosed
WO-2023116761-A1 PYRIMIDINE HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE 英矽智能科技知识产权有限公司 2023-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250145632-A1 Pyrimidine Heterocyclic Compound, Preparation Method Thereof and use Thereof in Medicine DPYD, TYMP, NUDT1 KEAP1 1708/4885PTPRC 1906/4885PTPN2 1279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.